Technical Analysis for CRDF - Cardiff Oncology, Inc.

Grade Last Price % Change Price Change
D 2.59 2.17% 0.06
CRDF closed down 3.44 percent on Wednesday, November 20, 2024, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 2.17%
Narrow Range Bar Range Contraction 2.17%
Wide Bands Range Expansion 2.17%
Oversold Stochastic Weakness 2.17%
MACD Bearish Centerline Cross Bearish -1.34%
Doji - Bullish? Reversal -1.34%
Wide Bands Range Expansion -1.34%
Oversold Stochastic Weakness -1.34%
NR7 Range Contraction 0.19%
Narrow Range Bar Range Contraction 0.19%

   Recent Intraday Alerts

Alert Time
Up 2% 2 minutes ago
60 Minute Opening Range Breakout about 1 hour ago
Up 1% about 1 hour ago
Down 2 % about 2 hours ago
Fell Below Previous Day's Low about 3 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cardiff Oncology, Inc. Description

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Pharmaceutical Solid Tumors Drugs Cancer Treatment Oncology Phosphates Acute Myeloid Leukemia Chemotherapy Lymphoma Prostate Cancer Antineoplastic Drugs Colorectal Cancer Leukemia Targeted Therapy Advanced Solid Tumors Solid Tumor Cancers Adenosine Metastatic Colorectal Cancer Resistant Prostate Cancer Metastatic Castration Resistant Prostate Cancer Nektar Therapeutics

Is CRDF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.42
52 Week Low 1.1501
Average Volume 807,719
200-Day Moving Average 3.09
50-Day Moving Average 2.84
20-Day Moving Average 3.11
10-Day Moving Average 2.99
Average True Range 0.32
RSI (14) 40.48
ADX 29.56
+DI 18.35
-DI 23.17
Chandelier Exit (Long, 3 ATRs) 3.41
Chandelier Exit (Short, 3 ATRs) 3.48
Upper Bollinger Bands 3.98
Lower Bollinger Band 2.24
Percent B (%b) 0.17
BandWidth 55.91
MACD Line -0.05
MACD Signal Line 0.07
MACD Histogram -0.1255
Fundamentals Value
Market Cap 113.03 Million
Num Shares 44.7 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -2.75
Price-to-Sales 174.60
Price-to-Book 1.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.76
Resistance 3 (R3) 2.77 2.71 2.72
Resistance 2 (R2) 2.71 2.66 2.71 2.70
Resistance 1 (R1) 2.62 2.62 2.59 2.61 2.69
Pivot Point 2.56 2.56 2.55 2.56 2.56
Support 1 (S1) 2.47 2.51 2.44 2.46 2.37
Support 2 (S2) 2.41 2.47 2.41 2.36
Support 3 (S3) 2.32 2.41 2.34
Support 4 (S4) 2.31